摘要
目的 探讨肺心合剂治疗肺心病急性发作期的部分作用机制。方法 将66只雄性Wistar大鼠随机分为正常对照组、MCT组、硝苯吡啶(Nif)组及肺心合剂低、中、高剂量治疗组,分别于造模后14d灌胃相应药物,连续用药8d。采用改良右心导管术测定肺血流动力学参数,以非平衡法测定静脉血浆ET-1水平;处死大鼠后,称量肺湿重(wW)、右心室自由壁(RV)重和左心室及室间隔(LV+S)重,计算右心肥厚指数(RV/LV+S)。结果 肺心合剂各剂量组及Nif组大鼠的MPAP、wW、RV/LV+S及血浆ET-1水平均明显降低,以肺心合剂高剂量组效果最好。结论 肺心合剂能有效降低肺动脉高压,改善心功能,其作用机制可能与降低血浆ET-1水平有关。
Objective: To investigate the mechanism of Feixin Mixture (FXM) on experimental pulmonary heart disease in acute episode period(EPHDA) by means of measuring the level of plasma ET - 1. Methods: Adult mate Wister rats were given a single dose of subcutaneous monocrotaline (50mg/kg) to induce the model of EPHDA. 66 rat were randomly divided into normal control group, EPHDA model group and Nifedipine group(n=11). Then treated with gastric infusion of normal saline, FXM or Nifedipine respectively. The parameters of pulmonary hemodynamics were monitored by Gould3400 polygraph system through the cannulation of polyvinyl tube . Right ventricle and left ventricle added with interventricular septum weight ratio, the lung wet weight were measured. The level of plasma ET - 1 was determined by the method of nonequilibrium. Results: FXM and Nifedipine significantly inhibited the progression of pulmonary artery pressure. It decreased the right heart index, and reduced the lung wet weight and the level of plasma ET-1. Conclusion: FXM is able to reduce the pulmonary hypertension and to improve the heart function. It' s mechanisms may be related to reducing the level of plasma ET - 1.
出处
《中国中医急症》
2003年第6期549-550,共2页
Journal of Emergency in Traditional Chinese Medicine
基金
四川省中医管理局科研基金(No.96031)
